<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The majority of the <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, present in patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, are directed against conformational <z:chebi fb="0" ids="53000">epitopes</z:chebi> in beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I. beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I is an anionic <z:chebi fb="0" ids="16247">phospholipid</z:chebi>-binding 50-kDa plasma protein whose physiological role is not clear </plain></SENT>
<SENT sid="1" pm="."><plain>Here we investigate the role of beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I in the phagocytosis of phosphatidylserine-expressing platelet microvesicles and the effect of autoantibodies to beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I on this process </plain></SENT>
<SENT sid="2" pm="."><plain>We labelled the <z:chebi fb="0" ids="18154">glycans</z:chebi> of beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I with <z:chebi fb="0" ids="51107">BODIPY</z:chebi> (<z:chebi fb="0" ids="51107">4,4-difluoro-4-bora-3a,4a-diaza-s-indacene</z:chebi>)-<z:chebi fb="0" ids="35362">hydrazide</z:chebi> without affecting its <z:chebi fb="0" ids="16247">phospholipid</z:chebi> binding capacity </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="51107">BODIPY</z:chebi>-beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I bound to platelet microvesicles in a concentration-dependent manner and promoted the phagocytosis of platelet microvesicles by <z:chebi fb="0" ids="46941">THP</z:chebi>-1 derived macrophages in vitro at physiological plasma concentrations with a half maximal effect at approximately 10 microg/ml </plain></SENT>
<SENT sid="4" pm="."><plain>beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I-stimulated phagocytosis was inhibited by annexin A5 and the phosphatidylserine-binding C1C2 fragment of lactadherin </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, immunoaffinity purified beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I-dependent <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> from five patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> inhibited the phagocytosis in a concentration-dependent manner </plain></SENT>
<SENT sid="6" pm="."><plain>These studies suggest that the binding of beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I to phosphatidylserine-expressing procoagulant platelet microvesicles may promote their clearance by phagocytosis and autoantibodies to beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I may inhibit this process to induce a procoagulant state </plain></SENT>
</text></document>